(EMAILWIRE.COM, July 06, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, notes the stark influx of trading volume for shares of Sunshine Heart (SSH) and identifies the company's pending catalysts as reasons to believe that even higher prices may yet be in store for the stock.
Sunshine Heart (SSH) had been a stock to watch anyway over the past trading week thanks to growing trading volume and increased awareness about the company's novel medical device that could make a huge impact in the future treatment of Class III heart failure. Sunshine's C-Pulse Heart Assist System, as described earlier this week, is a small device that is implanted in a patient's heart, but because it is implanted outside of the bloodstream it allows quality-of-life conveniences - such as the ability to be disconnected (for showering, for example) - that could quickly make it the market leader in meeting the unmet medical need of Class III and ambulatory Class IV heart failure.
Early studies have also shown that C-Pulse may not only be able to steady the effects of heart failure, but perhaps reverse them, as well.
The technology and potential behind this breakthrough product may finally be getting noticed, if Friday's trading is any indication. Volume had been growing for the duration of a couple of weeks now, but trading during the last two days of the week were monumentally huge, in comparison to previous trading patterns, and Friday's volume influx came with a price spike of nearly sixty percent - and higher at points during the intra-day.
With multiple catalysts pending this year, Sunshine Heart is not one to let too far out of sight. When lightly-traded companies such as this one with potentially huge technology start to move - things could materialize very quickly, as evidenced by Friday's trading.
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, growth stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.